Burning Rock narrows losses with drug research as new driver
The cancer testing company has finally reduced the flow of red ink and is generating a growing income stream from drug research services Key Takeaways: Burning Rock's net loss…
BNR.US
Recent Articles
RELATED ARTICLES
-
BRIEF: Burning Rock returns to revenue growth as loss narrows
BNR.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
Discover hidden China stock gems in our weekly newsletter